+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaccines Market by Indication, Route of Administration, Type, Valence - Global Forecast to 2028

  • PDF Icon


  • 229 Pages
  • March 2021
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 4986121
UP TO OFF until Sep 30th 2023
Vaccines Market by Indication (Pneumococcal, Influenza, Rotavirus, Hepatitis, COVID-19), Route of Administration (Intramuscular, Subcutaneous, Oral), Type (Inactivated, Live Attenuated, Subunit Vaccines), Valence (Multivalent, Monovalent) - Forecast to 2028

The global vaccines market is valued at $187 billion in 2021, with COVID-19 vaccines contributing $137 billion.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The vaccine market's growth is mainly attributed to the high prevalence of diseases, technological advancements in the vaccines industry, increasing government initiatives towards immunization, and a strong pipeline for vaccines. In addition, emerging markets are expected to offer significant growth opportunities for players operating in the vaccines market. However, product recalls and inadequate access to vaccines are the key factors expected to hinder the growth of the vaccines market.

Based on the disease indication, in 2021, the COVID-19 vaccines segment is estimated to account for the largest share of the total vaccines market. With the rise in coronavirus cases globally, joint efforts by organizations and companies to speed up vaccine development are contributing to the large share. This is followed by the pneumococcal vaccines segment.

Based on the type the subunit and conjugate vaccines segment is estimated to account for the largest share of the global vaccines market in 2021 due to long term immunity and high safety and stability compared to other antigens, and easy self-administration by the patient. However, the inactivated vaccines are expected to grow at the highest CAGR as the COVID-19 pandemic contributes to it because many of the Covid-19 vaccines launched contain the inactivated antigen.

An in-depth analysis of the geographical scenario of the vaccines market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is estimated to account for the largest share of the global vaccines market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa.

The key players operating in the global vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Scope of the Report:

Global Vaccines Market, by Indication

  • Pneumococcal Diseases
  • Influenza
  • Human Papilloma Virus (HPV)
  • DTP
  • Meningococcal Disease
  • MMR
  • Rotavirus
  • Poliomyelitis (Polio)
  • Hepatitis
  • Other Indications

Global Vaccines Market, by Route of Administration

  • Intramuscular
  • Subcutaneous
  • Oral
  • Other Routes of Administration

Global Vaccines Market, by Type

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit and Conjugate vaccines
  • Toxoid Vaccines
  • Combination Vaccines

Global Vaccines Market, by Valence

  • Monovalent
  • Polyvalent (Multivalent)

Global COVID-19 Vaccines Market

  • Prevalence
  • COVID-19 Vaccines Market Size and Forecast
  • Initiatives for Coronavirus Vaccine Development
  • Authorized Vaccines & Phase 3 Vaccine Candidates
  • COVID-19 Vaccine Pipeline Analysis
  • Purchase Data for COVID-19 Vaccines
  • Vaccination Coverage

Global Vaccines Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation Approach Approach Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Market Dynamics
4.2.1. Drivers Strong Product Pipeline for Vaccines Increasing Government Focus on Immunization Programs Technological Advancements in Vaccine Administration
4.2.2. Restraints High Costs Involved in Vaccine Development Long Timelines of Vaccine Manufacturing
4.2.3. Opportunities Rising Prevalence of Diseases Growing Focus on Therapeutic Vaccines Growth Prospects in Emerging Markets Increasing Use of Adjuvants in Vaccines
4.2.4. Challenges Product Recalls Inadequate Access to Vaccines
5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region
6. Global Vaccines Market, by Indication
6.1. Introduction
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papillomavirus (HPV)
6.5. Diphtheria, Tetanus, and Pertussis (DTP)
6.6. Meningococcal Disease
6.7. Measles, Mumps, and Rubella (MMR)
6.8. Rotavirus
6.9. Poliomyelitis (Polio)
6.10. Hepatitis
6.11. Other Indications
7. Global Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other Routes of Administration
8. Global Vaccines Market, by Type
8.1. Introduction
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live-Attenuated Vaccines
8.5. Toxoid Vaccines
8.6. Combination Vaccines
9. Global Vaccines Market, by Valence
9.1. Introduction
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines
10. Global COVID-19 Vaccines Market
10.1. Introduction
10.2. Prevalence
10.3. COVID-19 Market Size & Forecast
10.4. Initiatives for Coronavirus Vaccine Development
10.5. Authorized Vaccines & Phase 3 Vaccine Candidates
10.6. COVID-19 Vaccine Pipeline Analysis
10.7. Purchase Data for COVID-19 Vaccines
10.8. Vaccination Coverage
11. Global Vaccines Market, by Geography
11.1. Introduction
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. U.K.
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe (RoE)
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Rest of Asia-Pacific (RoAPAC)
11.5. Latin America
11.6. Middle East & Africa (MEA)
12. Competitive Landscape
12.1. Introduction
12.2. Key Growth Strategies
12.3. Competitive Benchmarking
12.4. Market Share Analysis
13. Company Profiles
13.1. Sanofi
13.1.1. Business Overview
13.1.2. Financial Overview
13.1.3. Product Portfolio
13.1.4. Product Pipeline
13.1.5. Strategic Developments
13.2. Merck & Co., Inc.
13.2.1. Business Overview
13.2.2. Financial Overview
13.2.3. Product Portfolio
13.2.4. Product Pipeline
13.2.5. Strategic Developments
13.3. GlaxoSmithKline plc.
13.3.1. Business Overview
13.3.2. Financial Overview
13.3.3. Product Portfolio
13.3.4. Product Pipeline
13.3.5. Strategic Developments
13.4. Pfizer, Inc.
13.4.1. Business Overview
13.4.2. Financial Overview
13.4.3. Product Portfolio
13.4.4. Product Pipeline
13.4.5. Strategic Developments
13.5. Johnson & Johnson
13.5.1. Business Overview
13.5.2. Financial Overview
13.5.3. Product Portfolio
13.5.4. Product Pipeline
13.5.5. Strategic Developments
13.6. Daiichi Sankyo Co., Ltd.
13.6.1. Business Overview
13.6.2. Financial Overview
13.6.3. Product Portfolio
13.6.4. Product Pipeline
13.6.5. Strategic Developments
13.7. Takeda Pharmaceutical Company Limited
13.7.1. Business Overview
13.7.2. Financial Overview
13.7.3. Product Portfolio
13.7.4. Product Pipeline
13.7.5. Strategic Developments
13.8. CSL Limited
13.8.1. Business Overview
13.8.2. Financial Overview
13.8.3. Product Portfolio
13.8.4. Product Pipeline
13.8.5. Strategic Developments
13.9. Emergent BioSolutions Inc.
13.9.1. Business Overview
13.9.2. Financial Overview
13.9.3. Product Portfolio
13.9.4. Product Pipeline
13.9.5. Strategic Developments
13.10. AstraZeneca PLC
13.10.1. Business Overview
13.10.2. Financial Overview
13.10.3. Product Portfolio
13.10.4. Strategic Developments
14. Appendix
14.1. Questionnaire
14.2. Available Customization



Companies Mentioned

  • Sanofi
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Daiichi Sankyo Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • AstraZeneca PLC